IO Biotech Inc. (IOBT)
IO Biotech, Inc. - IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination withKEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech, Inc. - IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination withKEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
There are no comments here yet...